IL17A and COVID-19: Since pro-inflammatory cytokines such as IL-4 and IL-17A are strongly correlated with COVID-19 severity and mortality, a decrease in these cytokine levels through inhibition of Th2 and Th17 differentiation seems to be beneficial in improving the health of COVID-19 patients and in preventing lung pathology.